Search Results - Riva, A.

  • Showing 1 - 2 results of 2
Refine Results
  1. 1
    Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial

    Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epiderman growth factor receptor 2-normal,... by Eiermann, W., Pienkowski, T., Crown, J., Sadeghi, S., Chan, Arlene, Saleh, M., Sehdev, S., Provencher, L., Semiglazov, V., Press, M., Sauter, G., Lindsay, M., Riva, A., Buyse, M., Drevot, P., Taupin, H., Mackey, J.

    Published 2011
    Get full text
  2. 2
    Adjuvant trastuzumab in HER2-positive breast cancer.

    Adjuvant trastuzumab in HER2-positive breast cancer. by Slamon, D., Eiermann, W., Robert, N., Pienkowski, T., Martin, M., Press, M., Mackey, J., Glaspy, J., Chan, Arlene, Pawlicki, M., Pinter, T., Valero, V., Liu, M., Sauter, G., von Minckwitz, G., Visco, F., Bee, V., Buyse, M., Bendahmane, B., Tabah-Fisch, I., Lindsay, M., Riva, A., Crown, J., Breast, C.

    Published 2011
    Get full text

Search Tools: